Is long-term follow-up solely by imaging tests safe in non-operated pancreatic neuroendocrine tumors?
INTRODUCTION: the diagnosis of asymptomatic sporadic nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) has increased significantly due to the widespread use of high-resolution imaging tests, which is why the most appropriate management at the time of diagnosis is the subject of debate, as is how to follow-up patients.
AIMS: the objective of this study was to analyze the frequency of imaging and endoscopic studies performed during long-term follow-up.
METHODS: a retrospective review was performed of a database collected between January 2008 and December 2020 of patients with an incidental diagnosis of small NF-PNETs; follow-up was closed in March 2023. The imaging tests performed at the time of diagnosis and long-term follow-up were recorded. Growing less than 1 mm per year has not been considered as a worrisome feature. Follow-up was performed through imaging tests, considering endoscopic cytology for lesions with a faster grow rate.
RESULTS: fifty-eight patients were included; the median age was 69 years. The initial mean size of the lesions studied was 12.79 mm (5-27). Follow-up was carried out only with computed tomography (CT) or magnetic resonance imaging (MRI). The initial size did not influence the behavior of the lesion in a statistically significant manner. Twenty-eight tumors (45 %) increased in size, with a growth equal to or less than 4 mm in 24 cases. The mean follow-up time was 82.41 months (12-164). No patient developed metastasis or died from PNET progression.
CONCLUSIONS: the follow-up of neuroendocrine tumors of small size can be performed safely with only imaging tests.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:116 |
|---|---|
| Enthalten in: |
Revista espanola de enfermedades digestivas - 116(2024), 4 vom: 27. Apr., Seite 209-215 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Polette, Daniela [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 17.04.2024 Date Revised 17.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.17235/reed.2023.9293/2022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365013102 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365013102 | ||
| 003 | DE-627 | ||
| 005 | 20240417232259.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.17235/reed.2023.9293/2022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM365013102 | ||
| 035 | |a (NLM)38010101 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Polette, Daniela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is long-term follow-up solely by imaging tests safe in non-operated pancreatic neuroendocrine tumors? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2024 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: the diagnosis of asymptomatic sporadic nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) has increased significantly due to the widespread use of high-resolution imaging tests, which is why the most appropriate management at the time of diagnosis is the subject of debate, as is how to follow-up patients | ||
| 520 | |a AIMS: the objective of this study was to analyze the frequency of imaging and endoscopic studies performed during long-term follow-up | ||
| 520 | |a METHODS: a retrospective review was performed of a database collected between January 2008 and December 2020 of patients with an incidental diagnosis of small NF-PNETs; follow-up was closed in March 2023. The imaging tests performed at the time of diagnosis and long-term follow-up were recorded. Growing less than 1 mm per year has not been considered as a worrisome feature. Follow-up was performed through imaging tests, considering endoscopic cytology for lesions with a faster grow rate | ||
| 520 | |a RESULTS: fifty-eight patients were included; the median age was 69 years. The initial mean size of the lesions studied was 12.79 mm (5-27). Follow-up was carried out only with computed tomography (CT) or magnetic resonance imaging (MRI). The initial size did not influence the behavior of the lesion in a statistically significant manner. Twenty-eight tumors (45 %) increased in size, with a growth equal to or less than 4 mm in 24 cases. The mean follow-up time was 82.41 months (12-164). No patient developed metastasis or died from PNET progression | ||
| 520 | |a CONCLUSIONS: the follow-up of neuroendocrine tumors of small size can be performed safely with only imaging tests | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Busquets, Juli |e verfasserin |4 aut | |
| 700 | 1 | |a Secanella Medayo, Lluis |e verfasserin |4 aut | |
| 700 | 1 | |a Sorribas Grifell, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Peláez Serra, Núria |e verfasserin |4 aut | |
| 700 | 1 | |a Uribe, Catalina |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Carnicero, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Salord Vila, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Guerrero, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Vercher-Conejero, Jose Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Teulé, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Fabregat, Joan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de enfermedades digestivas |d 1993 |g 116(2024), 4 vom: 27. Apr., Seite 209-215 |w (DE-627)NLM012635049 |x 1130-0108 |7 nnns |
| 773 | 1 | 8 | |g volume:116 |g year:2024 |g number:4 |g day:27 |g month:04 |g pages:209-215 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.17235/reed.2023.9293/2022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 116 |j 2024 |e 4 |b 27 |c 04 |h 209-215 | ||